Dr. Sei Y. Chung, M.D.
ENT (Otolaryngology) (Otolaryngology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers New Jersey Medical School (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 176
Licensed in Texas since 2022, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Rutgers New Jersey Medical School
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngology Physician primary
TX license T7187 (first issued 2022; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Parkland Health & Hospital System Dallas, TX
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 176
- Services billed
- 536
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of nasal passages using an endoscope | 39 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 19 payments worth $2,117 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $1,560 |
|---|---|
| GlaxoSmithKline, LLC. | $240 |
| Medtronic, Inc. | $123 |
| Genzyme Corporation | $111 |
| Integra Lifesciences Corporation | $83.33 |
| Travel and Lodging | $1,158 |
|---|---|
| Food and Beverage | $959 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 6, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $278 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $268 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $219 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $35.25 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $35.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $26,110 in research payments for these studies, mostly to the institutions running them.
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company · Recruiting · NCT06338995 - Realiti-n: a multinational, observational study to evaluate the real-w
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.